ArticleHeart (British Cardiac Society)2022
Efficacy of treat-and-repair strategy for atrial septal defect with pulmonary arterial hypertension.
Article in Heart (British Cardiac Society), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- The efficacy of the treat-repair-treat strategy for severe pulmonary arterial hypertension associated with congenital heart disease: a meta-analysis.BMC cardiovascular disorders · 2023Pooled it
- Treat-and-repair Strategy for Atrial Septal Defect with Eisenmenger Syndrome due to Pulmonary Arterial Hypertension.Internal medicine (Tokyo, Japan) · 2026Article
- Atrial Septal Defect Closure With Persistently Elevated Pulmonary Vascular Resistance.JACC. Case reports · 2026Article
- Hemodynamic Unmasking of Atrial Septal Defect After Pulmonary Arterial Hypertension Therapy: A Pathophysiologic Perspective.Clinical case reports · 2026Article
- Early postoperative treprostinil in for severe pulmonary arterial hypertension in a high-risk pediatric patient with complete atrioventricular septal defect: a case report.BMC cardiovascular disorders · 2026Article
- Pulmonary Arterial Hypertension-Specific Therapy for Atrial Septal Defects with Severe Pulmonary Arterial Hypertension.Pediatric cardiology · 2026Article
- Long-term efficacy of the treat-to-close strategy for patients with atrial septal defect-pulmonary artery hypertension and characteristics of indicated populations.Clinics (Sao Paulo, Brazil) · 2026Article
- Targeted Drugs, PADN, and Transcatheter Closure for Atrial Septal Defect-Associated Pulmonary Hypertension.JACC. Case reports · 2026Article
- A Case of Atrial Septal Defect Unveiled by the Treatment for Pulmonary Arterial Hypertension.Clinical case reports · 2026Article
- Atrial Septal Defects: From Embryology to Pediatric Pulmonary Hypertension.Journal of clinical medicine · 2025Review
- Pulmonary arterial hypertension treatment. A new era.International journal of cardiology. Congenital heart disease · 2025Review
- Inferior vena cava anomalous drainage into the left atrium with severe pulmonary arterial hypertension: a case report and review of management strategies.Frontiers in cardiovascular medicine · 2025Article
- Embracing the challenges of neonatal and paediatric pulmonary hypertension.The European respiratory journal · 2024Review
- Treat and Repair for Congenital Heart Disease and Pulmonary Hypertension: Not a Panacea.JACC. Advances · 2024Article
- Therapeutic effects of treat and repair strategy in pediatric patients with pulmonary arterial hypertension and simple congenital heart defects.Pulmonary circulation · 2024Article
- Feasibility of Treat and Repair Strategy in Congenital Heart Defects With Pulmonary Arterial Hypertension.JACC. Advances · 2024Article
- Long-term outcomes of transcatheter atrial septal defect closure: a single-center retrospective study.Frontiers in cardiovascular medicine · 2024Article
- Current Management and Future Directions for Pulmonary Arterial Hypertension Associated with Congenital Heart Disease.Journal of personalized medicine · 2023Review
- Outcomes in Patients with Pulmonary Arterial Hypertension Underwent Transcatheter Closure of an Atrial Septal Defect.Journal of clinical medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 13 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTherapeutic strategies for atrial septal defect (ASD) with severe pulmonary arterial hypertension (PAH) are controversial. This study aimed to evaluate the efficacy of PAH-specific medications and subsequent transcatheter closure (ie, treat-and-repair strategy) on clinical outcomes.
methodsWe enrolled 42 patients who were referred to 13 institutions for consideration of ASD closure with concomitant PAH and underwent the treat-and-repair strategy. The endpoint was cardiovascular death or hospitalisation due to heart failure or exacerbated PAH.
resultsAt baseline prior to PAH-specific medications, pulmonary to systemic blood flow ratio (Qp:Qs), pulmonary vascular resistance (PVR), and mean pulmonary artery pressure (PAP) were 1.9±0.8, 6.9±3.2 Wood units and 45±15 mm Hg. Qp:Qs was increased to 2.4±1.2, and PVR and mean PAP were decreased to 4.0±1.5 Wood units and 35±9 mm Hg at the time of transcatheter ASD closure after PAH-specific medications. Transcatheter ASD closure was performed without any complications. During a median follow-up period of 33 months (1-126 months) after transcatheter ASD closure, one older patient died and one patient was hospitalised due to heart failure, but the other patients survived with an improvement in WHO functional class. PAP was further decreased after transcatheter ASD closure.
conclusionsThe treat-and-repair strategy results in low complication and mortality rates with a reduction in PAP in selected patients with ASD complicated with PAH who have a favourable response of medical therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.